Mountain View, CA —In an effort to identify diseases earlier, Google is looking to identify the true definition of what it means to be in good health by using data, their enormous computing resources and an all-star research team led by Dr. Andrew Conrad. The research, named the Baseline Study, is establishing a baseline of a fully healthy human at the molecular level. By having this information, Google hopes to be able to detect diseases before they become life altering.

This proactive versus reactive approach will utilize the huge advancements of genomic mapping technology to identify any concerns. This unidentifiable information, combined with genetic history, holistic behaviors and natural reactions, will provide the baseline details that medical providers can use to diagnose any possible abnormalities that identify disease.

As patients are becoming actively involved in their own health discussion, Google is planning on including data from self tracking devices to be able to paint the entire picture. And while Google is taking giant steps into this space, they aren’t the only ones. Apple and Samsung have also announced initiatives to gather and track our health data.

We’re interested to know what you think. Would you be willing to share your health data if it meant preventing disease? How does your health history and willingness to share data, identifiable and unidentifiable, affect this decision?

Take the quick survey here and let us know your thoughts:


Posted By: Mike Martins

About the Author:

As Managing Director of Innovation and Insights for Syneos Health Communications, Leigh is responsible for building and scaling a global team of healthcare experts who together help life science leaders better understand the complex lives, influences and expectations of their customers. Specifically, they uncover actionable insights that fuel empathy and creativity; lead co-creation events that let marketers learn from peers, trends, and new possibilities; and help clients identify the most valuable and useful new customer experiences to create.

Leigh has worked with Fortune 1000 companies to craft their digital, mobile, social and CRM strategies for nearly 20 years.She’s worked for category-leading agencies in retail, public affairs, B2B technology, and higher education. Prior to moving to Syneos Health Communications, she held several leadership roles at our largest agency, GSW.  There, she founded an innovation practice fueled by the zeitgeist and spearheaded digital and innovation thinking across the business.

Leigh has taken a special interest in complex healthcare products that can change lives in meaningful ways. She was recently a strategic lead on the 3rd largest launch in pharmaceutical history: Tecfidera. Before that she had keys roles with Eli Lilly Oncology, Abbott Nutrition, Amgen Cardiovascular, and Eli Lilly Diabetes.

A critical part of Leigh’s work is trends and new ideas. Every year, she convenes a group of trend watchers from across our global network to identify the shifts most critical to healthcare marketers. This year, she led over 250 experts to experts to focus on the most important changes in the commercial, consumer, marketing, digital and healthcare landscapes. (See reports at

Leigh is a sought-after writer and speaker. Recognized as one of the most inspiring people in the pharmaceutical industry by PharmaVoice and Top 10 Innovation Catalysts of 2017 by MM&M, Leigh also was recognized  as a Rising Star by the Healthcare Businesswomen's Association (HBA) for her overt passion, industry thought leadership and significant contributions in new business, strategy and mentoring.